Medscape is available in 5 Language Editions – Choose your Edition here.



  • Author: Henry K Wong, MD, PhD; Chief Editor: Dirk M Elston, MD  more...
Updated: Jun 02, 2016

Practice Essentials

Urticaria, commonly referred to as hives, appears as raised, well-circumscribed areas of erythema and edema involving the dermis and epidermis that are very pruritic (see the image below). It may be acute (<6 wk) or chronic (>6 wk). Urticaria may be confused with a variety of other dermatologic diseases that are similar in appearance and are also pruritic; usually, however, it can be distinguished from these diseases by an experienced clinician.[1]

Urticaria developed after bites from an imported f Urticaria developed after bites from an imported fire ant.

Signs and symptoms

Information regarding history of previous urticaria and duration of rash and itching is useful for categorizing urticaria as acute, recurrent, or chronic. For chronic or recurrent urticaria, important considerations include previous causative factors and the effectiveness of various treatments, as follows[2] :

  • Precipitants, such as heat, cold, pressure, exercise, sunlight, emotional stress, or chronic medical conditions
  • Other medical conditions that can cause pruritus (usually without rash), such as diabetes mellitus, chronic renal insufficiency, primary biliary cirrhosis, or other nonurticarial dermatologic disorders
  • Family and personal medical history of angioedema - Characteristics of angioedema [1] include vasodilation and exudation of plasma into the deeper tissues more so than with simple urticaria; angioedema can occur with and without the wheals of simple urticaria and presents clinically as subcutaneous swelling that is generally nonpitting and nonpruritic; it can affect the mouth as well as  the mucosal surfaces of the respiratory and GI tracts, manifesting as hoarseness and GI upset; it can be a feature of anaphylaxis if the throat is involved, leading to airway compromise

For acute urticaria, the main consideration involves possible precipitants, such as the following[1] :

  • Recent illness
  • Medication use
  • IV radiocontrast media
  • Travel
  • Foods
  • New perfumes, hair dyes, detergents, lotions, creams, or clothes
  • Exposure to new pets (dander), dust, mold, chemicals, or plants
  • Pregnancy (usually occurs in last trimester and typically resolves spontaneously soon after delivery)
  • Contact with nickel, rubber, latex, industrial chemicals, and nail polish
  • Sun or cold exposure
  • Exercise
  • Alcohol ingestion [3]

Physicall urticaria is characterized by the following:

  • Blanchable, raised, palpable wheals, which can be linear, annular (circular), or arcuate (serpiginous); can occur on any skin area; are usually transient and migratory; and may coalesce rapidly to form large areas of erythematous, raised lesions that blanch with pressure
  • Dermographism or dermatographism (urticarial lesions resulting from light scratching)

The physical examination should focus on conditions that might precipitate urticaria or could be potentially life-threatening and include the following[1] :

  • Angioedema of the lips, tongue, or larynx
  • Individual urticarial lesions that are painful, long-lasting (>24 h), or ecchymotic or that leave residual hyperpigmentation or ecchymosis upon resolution are suggestive of urticarial vasculitis
  • Systemic signs or symptoms
  • Scleral icterus, hepatic enlargement, or tenderness
  • Thyromegaly
  • Pneumonia or bronchospasm (asthma)
  • Cutaneous evidence of bacterial or fungal infection

See Clinical Presentation for more detail.


Laboratory studies may be helpful, as follows:

  • Acute urticaria (<6 wk) - Laboratory studies generally are not indicated
  • Chronic or recurrent urticaria (>6 wk) - Basic laboratory studies should include complete blood count (CBC), erythrocyte sedimentation rate (ESR), thyroid-stimulating hormone (TSH), and antinuclear antibody (ANA) [4]

Other studies that may be considered include the following:

  • Imaging studies - Generally not indicated unless suggested by a specific symptom or sign [4]
  • Punch biopsy - If urticarial vasculitis is suspected

See Workup for more detail.


Acute urticaria may rarely progress to life-threatening angioedema or anaphylactic shock in a very short period, although anaphylactic shock is usually of rapid onset with no urticaria or angioedema.[5] Prehospital measures may include the following when there is concern for anaphylactic shock:

  • If associated angioedema is present, IM epinephrine
  • If associated bronchospasm is present, nebulized albuterol
  • Other measures may be appropriate, such as continuous ECG, blood pressure and pulse oximetry monitoring; administering intravenous crystalloids if the patient is hypotensive; and administering oxygen.
  • Diphenhydramine or hydroxyzine, if available

Management of urticaria is focused on treating the symptoms and typically is not altered by underlying etiology. The mainstay is avoidance of further exposure to the antigen causing urticaria. Pharmacologic treatment options include the following:

  • Antihistamines, primarily those that block H1 receptors with low sedating activity, such as fexofenadine, loratadine, desloratadine, cetirizine, and levocetirizine are first-line therapy [6, 7] ; these are preferred over diphenhydramine and hydroxyzine; H2 antihistamines, such as cimetidine, famotidine, and ranitidine, may have a role when used in combination with H1 antihistamines, although the benefit is unclear [8]
  • Doxepin
  • Omalizumab
  • Glucocorticoids
  • Epinephrine (controversial in acute urticaria)
  • Methotrexate, colchicine, dapsone, indomethacin, and hydroxychloroquine (for urticarial vasculitis) [9]
  • Patients with chronic or recurrent urticaria should be referred to a dermatologist for further evaluation and management.

Consultation with or referral to a dermatologist, allergist, immunologist, or rheumatologist may be appropriate in selected cases, particularly in cases of complicated, recurrent, refractory, severe, or chronic urticaria. Dermatology referral is mandatory if urticarial vasculitis is suspected.

See Treatment and Medication for more detail.



Urticaria, commonly referred to as hives, is the most frequent dermatologic disorder seen in the emergency department (ED). It appears as raised, well-circumscribed areas of erythema and edema involving the dermis and epidermis that are very pruritic. Urticaria may be acute (lasting <6 wk) or chronic (lasting >6 wk). A large variety of urticaria variants exist, including acute immunoglobulin E (IgE)–mediated urticaria, chemical-induced urticaria (non-IgE-mediated), autoimmune urticaria, cholinergic urticaria, cold urticaria, mastocytosis, periodic fever syndromes including Muckle-Wells syndrome, and many others.[2, 10] While acute urticaria is generally related to an exogenous allergen or acute infection, chronic urticaria is more likely to be associated with autoimmunity.[8, 11, 12]

Urticaria may be confused with a variety of other dermatologic diseases that are similar in appearance and are pruritic including atopic dermatitis (eczema), maculopapular drug eruptions, contact dermatitis, insect bites, erythema multiforme, pityriasis rosea, urticarial vasculitis, and others. Usually, however, the experienced clinician is able to distinguish urticaria from its mimickers owing to its distinctive appearance (see the images below), intensely pruritic nature, and complete blanching with pressure.[1]

Urticaria developed after bites from an imported f Urticaria developed after bites from an imported fire ant.
Urticaria associated with a drug reaction. Urticaria associated with a drug reaction.

Acute urticaria is most often a benign, self-limited skin disease. It usually occurs independently, but it may contribute to the more serious clinical manifestations of anaphylaxis: angioedema and anaphylactic shock. The etiologies of both acute and chronic urticaria are numerous (see Causes in Presentation). The etiologic agent is more likely to be identified in acute urticaria (40-60%) than in chronic urticaria (10-20%). The lesions of IgE-mediated urticaria usually last less than 24 hours and are often migratory, leaving no residual skin abnormalities. The lesions of urticarial vasculitis usually last longer, classically, but not always, longer than 24 hours.[8] They are both painful and pruritic and often leave purpuric and hyperpigmented lesions.[9] Unlike simple urticaria, urticarial vasculitis demonstrates leukocytoclastic vasculitis on histology. Like urticaria, it may occur with or without angioedema. It may be associated with systemic symptoms such as arthralgias and GI symptoms, which are more common in patients with low complement levels. Although it is most often idiopathic, it is more often associated with autoimmune diseases such as lupus and Sjögren syndrome, as well as viral infections, medications, and malignancy, when compared with classic urticaria.[13] If urticarial vasculitis is suspected, an autoimmune screen, including complement levels, should be included in the workup. Initial treatment options include antihistamines and NSAIDs.

For more information, see Medscape's Allergy Resource Center.



Urticaria results from the release of histamine, bradykinin, leukotriene C4, prostaglandin D2, and other vasoactive substances from mast cells and basophils in the dermis. These substances cause extravasation of fluid into the dermis, leading to the urticarial lesion. The intense pruritus of urticaria is a result of histamine released into the dermis. Histamine is the ligand for two membrane-bound receptors, the H1 and H2 receptors, which are present on many cell types. The activation of the H1 histamine receptors on endothelial and smooth muscle cells leads to increased capillary permeability. The activation of the H2 histamine receptors leads to arteriolar and venule vasodilation.[14, 15]

This process is caused by several mechanisms. The type I allergic IgE response is initiated by antigen-mediated IgE immune complexes that bind and cross-link Fc receptors on the surface of mast cells and basophils, thus causing degranulation with histamine release. The type II allergic response is mediated by cytotoxic T cells, causing deposits of immunoglobulins, complement, and fibrin around blood vessels. This leads to urticarial vasculitis. The type III immune-complex disease is associated with systemic lupus erythematosus and other autoimmune diseases that cause urticaria.[15]

Complement-mediated urticarias include viral and bacterial infections, serum sickness, and transfusion reactions. Urticarial transfusion reactions occur when allergenic substances in the plasma of the donated blood product react with preexisting IgE antibodies in the recipient. Certain drugs (opioids, vecuronium, succinylcholine, vancomycin, and others) as well as radiocontrast agents cause urticaria due to mast cell degranulation through a non—IgE-mediated mechanism. Urticaria from nonsteroidal anti-inflammatory drugs may be IgE-mediated or due to mast cell degranulation, and there may be significant cross-reactivity among the nonsteroidal anti-inflammatory drugs (NSAIDs) in causing urticaria and anaphylaxis.[16]

The physical urticarias in which some physical stimulus causes urticaria include immediate pressure urticaria, delayed pressure urticaria, cold urticaria, and cholinergic urticaria.[17, 18] For some urticarias, especially chronic urticarias, no cause can be found, despite exhaustive efforts—the so-called idiopathic urticarias, although most of these are chronic autoimmune urticaria as defined by a positive autologous serum skin test (ASST).[19] This test is not specific for autoantibodies against a specific antigen or diagnostic of a specific disease state.[20] To date, no reliable test exists to identify with certainty if chronic urticaria is autoimmune or nonautoimmune in the specific patient.[21, 22]



United States

Acute urticaria affects 15-20% of the general population at some time during their lifetime. Chronic urticaria affects 2-3% of individuals over their lifetime.[23]


The global frequency of urticaria is similar to that in the United States.


No variation in race is noted.


Incidence rates for acute urticaria are similar for men and women; chronic urticaria occurs more frequently in women (60%).


Urticaria can occur in any age group, although chronic urticaria is more common in the fourth and fifth decades.



Pruritus (itching) and rash are the primary manifestations of urticaria, and permanent hyperpigmentation or hypopigmentation is rare.

The prognosis in acute urticaria is excellent. Acute urticaria is usually self-limited, and individual lesions commonly resolve within 24 hours; however, episodes may recur for up to 6 weeks.

The prognosis in chronic urticaria is more guarded and depends on the comorbid disease causing the urticaria as well as the response to therapy. Chronic urticaria lasts more than 6 weeks.

Acute and chronic urticaria can result in severely impaired quality of life from pruritus and associated sleeplessness, as well as anxiety and depression. The depression can be severe enough to lead to suicide in rare cases. Additionally, many of the diseases associated with chronic urticaria may cause significant morbidity and mortality.


Patient Education

Education regarding avoidance of the suspected offending allergen is essential.

For patient education resources, see the Allergies Center and Skin Conditions and Beauty Center. Also see the patient education article Hives and Angioedema.

Contributor Information and Disclosures

Henry K Wong, MD, PhD Professor and Chairman, Department of Dermatology, University of Arkansas for Medical Sciences College of Medicine

Henry K Wong, MD, PhD is a member of the following medical societies: American Academy of Dermatology, International Society for Cutaneous Lymphomas, Medical Dermatology Society, Society for Investigative Dermatology

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Seattle GEnetics, Actillion, Celgene<br/>Serve(d) as a speaker or a member of a speakers bureau for: Amgen<br/>Received income in an amount equal to or greater than $250 from: Celgene<br/>Received honoraria from Amgen for speaking and teaching; Received grant/ Received grant/research funds from Celgene for none; Received grant/research funds from Abbott Labs for independent contractor; Received grant/research funds from Amgen for none; Received honoraria from Seattle Genetics for consulting. for: Actelion-Advisory board, grants;Seattle Genetics - Advisory board.


Mallory Shiver, MD Resident Physician, Department of Dermatology, University of Arkansas for Medical Sciences College of Medicine

Mallory Shiver, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Arkansas Foundation for Skin Cancer, Christian Medical and Dental Associations

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Steven A Conrad, MD, PhD Chief, Department of Emergency Medicine; Chief, Multidisciplinary Critical Care Service, Professor, Department of Emergency and Internal Medicine, Louisiana State University Health Sciences Center

Steven A Conrad, MD, PhD is a member of the following medical societies: American College of Chest Physicians, American College of Critical Care Medicine, American College of Emergency Physicians, American College of Physicians, International Society for Heart and Lung Transplantation, Louisiana State Medical Society, Shock Society, Society for Academic Emergency Medicine, Society of Critical Care Medicine

Disclosure: Nothing to disclose.


Mark W Fourre, MD Associate Clinical Professor, Department of Surgery, University of Vermont School of Medicine; Program Director, Department of Emergency Medicine, Maine Medical Center

Disclosure: Nothing to disclose.

  1. Frigas E, Park MA. Acute urticaria and angioedema: diagnostic and treatment considerations. Am J Clin Dermatol. 2009. 10(4):239-50. [Medline].

  2. Poonawalla T, Kelly B. Urticaria : a review. Am J Clin Dermatol. 2009. 10(1):9-21. [Medline].

  3. Ribeiro F, Sousa N, Carrapatoso I, Segorbe Luís A. Urticaria after ingestion of alcoholic beverages. J Investig Allergol Clin Immunol. 2014. 24(2):122-3. [Medline].

  4. Irinyi B, Szeles G, Gyimesi E, Tumpek J, Heredi E, Dimitrios G, et al. Clinical and laboratory examinations in the subgroups of chronic urticaria. Int Arch Allergy Immunol. 2007. 144(3):217-25. [Medline].

  5. Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010 Feb. 125(2 Suppl 2):S161-81. [Medline].

  6. [Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43. [Medline].

  7. Sharma M, Bennett C, Carter B, Cohen SN. H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review. J Am Acad Dermatol. 2015 Aug 4. [Medline].

  8. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May. 133(5):1270-7. [Medline].

  9. Brown NA, Carter JD. Urticarial vasculitis. Curr Rheumatol Rep. 2007 Aug. 9(4):312-9. [Medline].

  10. Najib U, Sheikh J. An update on acute and chronic urticaria for the primary care provider. Postgrad Med. 2009 Jan. 121(1):141-51. [Medline].

  11. Viegas LP, Ferreira MB, Kaplan AP. The maddening itch: an approach to chronic urticaria. J Investig Allergol Clin Immunol. 2014. 24(1):1-5. [Medline].

  12. Darlenski R, Kazandjieva J, Zuberbier T, Tsankov N. Chronic urticaria as a systemic disease. Clin Dermatol. 2014 May-Jun. 32(3):420-3. [Medline].

  13. Bolognia JL, Jorizzo JL, Shaffer JV. Dermatology. 3rd ed. Philadelphia, Pa: Elsevier Saunders; 2012.

  14. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol. 2007. 87(3):196-205. [Medline].

  15. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008 Sep. 122(3):569-73. [Medline].

  16. Viola M, Quaratino D, Gaeta F, Rumi G, Caruso C, Romano A. Cross-reactive reactions to nonsteroidal anti-inflammatory drugs. Curr Pharm Des. 2008. 14(27):2826-32. [Medline].

  17. [Guideline] Magerl M, Borzova E, Gimrnez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, et al. The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy. 2009 Dec. 64(12):1715-21. [Medline].

  18. Kasperska-Zajac A, Jasinska T, Grzanka A, Kowalik-Sztylc A. Markers of systemic inflammation in delayed pressure urticaria. Int J Dermatol. 2012 Nov 1. [Medline].

  19. Tong LJ, Balakrishnan G, Kochan JP, Kinét JP, Kaplan AP. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol. 1997 Apr. 99(4):461-5. [Medline].

  20. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009 Sep. 64(9):1256-68. [Medline].

  21. Philpott H, Kette F, Hissaria P, Gillis D, Smith W. Chronic urticaria: the autoimmune paradigm. Intern Med J. 2008 Nov. 38(11):852-7. [Medline].

  22. Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2012 Nov 15. [Medline].

  23. [Guideline] Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015 Mar. 45 (3):547-65. [Medline].

  24. Hossler EW. Caterpillars and moths: Part I. Dermatologic manifestations of encounters with Lepidoptera. J Am Acad Dermatol. 2010 Jan. 62(1):1-10; quiz 11-2. [Medline].

  25. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009 Jun. 39(6):777-87. [Medline].

  26. Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol. 2008 Dec. 20(6):709-16. [Medline].

  27. Guldbakke KK, Khachemoune A. Etiology, classification, and treatment of urticaria. Cutis. 2007 Jan. 79(1):41-9. [Medline].

  28. Bains SN, Hsieh FH. Current approaches to the diagnosis and treatment of systemic mastocytosis. Ann Allergy Asthma Immunol. 2010 Jan. 104(1):1-10; quiz 10-2, 41. [Medline].

  29. Goldfinger S. The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc. 2009. 120:413-8. [Medline]. [Full Text].

  30. Nichols KM, Cook-Bolden FE. Allergic skin disease: major highlights and recent advances. Med Clin North Am. 2009 Nov. 93(6):1211-24. [Medline].

  31. Brodell LA, Beck LA. Differential diagnosis of chronic urticaria. Ann Allergy Asthma Immunol. 2008 Mar. 100(3):181-8; quiz 188-90, 215. [Medline].

  32. Sánchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012 Nov. 5 (11):125-47. [Medline].

  33. Botto NC, Warshaw EM. Solar urticaria. J Am Acad Dermatol. 2008 Dec. 59(6):909-20; quiz 921-2. [Medline].

  34. Kaplan AP. Therapy of chronic urticaria: a simple, modern approach. Ann Allergy Asthma Immunol. 2014 May. 112(5):419-425. [Medline].

  35. Sype JW, Khan IA. Prolonged QT interval with markedly abnormal ventricular repolarization in diphenhydramine overdose. Int J Cardiol. 2005 Mar 18. 99(2):333-5. [Medline].

  36. [Guideline] Fine LM, Bernstein JA. Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines. Curr Allergy Asthma Rep. 2015 Jun. 15 (6):30. [Medline].

  37. Sil A, Tripathi SK, Chaudhuri A, Das NK, Hazra A, Bagchi C, et al. Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. J Dermatolog Treat. 2012 Nov 19. [Medline].

  38. Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. 2000 Nov. 36(5):462-8. [Medline].

  39. Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev. 2012 Mar 14. 3:CD008596. [Medline].

  40. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 1997 May. 31(5):633-5. [Medline].

  41. Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med. 1995 Nov. 26(5):547-51. [Medline].

  42. Bluestein HM, Hoover TA, Banerji AS, Camargo CA Jr, Reshef A, Herscu P. Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol. 2009 Dec. 103(6):502-7. [Medline].

  43. Rajan JP, Simon RA, Bosso JV. Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticaria. J Allergy Clin Immunol Pract. 2014 Mar-Apr. 2(2):168-71. [Medline].

  44. Simons FE. H1-Antihistamines: more relevant than ever in the treatment of allergic disorders. J Allergy Clin Immunol. 2003 Oct. 112(4 Suppl):S42-52. [Medline].

  45. Balaraman B, Bergstrom KG. Beyond antihistamines: treating chronic urticaria. J Drugs Dermatol. 2009 Nov. 8(11):1043-8. [Medline].

  46. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009. J Allergy Clin Immunol. 2010 Jan. 125(1):85-97. [Medline].

  47. Okubo Y, Shigoka Y, Yamazaki M, Tsuboi R. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. J Dermatolog Treat. 2013 Apr. 24(2):153-60. [Medline].

  48. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 7. 368(10):924-35. [Medline].

  49. Kai AC, Flohr C, Grattan CE. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis. Clin Exp Dermatol. 2014 Apr 23. [Medline].

  50. Lang DM. Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria. Drugs Today (Barc). 2015 Jun. 51 (6):367-74. [Medline].

  51. Wan KS. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatolog Treat. 2009. 20(4):194-7. [Medline].

  52. Serhat Inaloz H, Ozturk S, Akcali C, Kirtak N, Tarakcioglu M. Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. J Dermatol. 2008 May. 35(5):276-82. [Medline].

  53. Kessel A, Toubi E. Low-dose cyclosporine is a good option for severe chronic urticaria. J Allergy Clin Immunol. 2009 Apr. 123(4):970; author reply 970-1. [Medline].

Urticaria developed after bites from an imported fire ant.
Urticaria associated with a drug reaction.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.